SG Americas Securities LLC Sells 10,669 Shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY)

SG Americas Securities LLC decreased its position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) by 69.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,780 shares of the biopharmaceutical company’s stock after selling 10,669 shares during the period. SG Americas Securities LLC’s holdings in CymaBay Therapeutics were worth $113,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. New York State Common Retirement Fund increased its position in CymaBay Therapeutics by 39.9% during the third quarter. New York State Common Retirement Fund now owns 64,404 shares of the biopharmaceutical company’s stock valued at $960,000 after acquiring an additional 18,381 shares during the last quarter. Vanguard Group Inc. increased its position in CymaBay Therapeutics by 11.6% during the third quarter. Vanguard Group Inc. now owns 5,747,587 shares of the biopharmaceutical company’s stock valued at $85,697,000 after acquiring an additional 598,707 shares during the last quarter. Emerald Mutual Fund Advisers Trust bought a new position in CymaBay Therapeutics during the third quarter valued at $12,073,000. Emerald Advisers LLC bought a new position in CymaBay Therapeutics during the third quarter valued at $14,668,000. Finally, Jennison Associates LLC increased its position in CymaBay Therapeutics by 112.7% during the third quarter. Jennison Associates LLC now owns 3,555,274 shares of the biopharmaceutical company’s stock valued at $53,009,000 after acquiring an additional 1,883,742 shares during the last quarter. Institutional investors own 95.03% of the company’s stock.

Insider Activity

In other news, Director Janet Dorling sold 6,000 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $31.97, for a total value of $191,820.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 7.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on CBAY shares. StockNews.com started coverage on shares of CymaBay Therapeutics in a research note on Friday. They set a “sell” rating for the company. Piper Sandler reissued a “neutral” rating and set a $32.50 target price (down from $33.00) on shares of CymaBay Therapeutics in a research note on Wednesday, February 14th. Lifesci Capital lowered shares of CymaBay Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 14th. Jonestrading reissued a “hold” rating on shares of CymaBay Therapeutics in a research note on Tuesday, February 13th. Finally, BTIG Research reissued a “neutral” rating on shares of CymaBay Therapeutics in a research note on Tuesday, February 13th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $28.65.

CymaBay Therapeutics Price Performance

NASDAQ:CBAY opened at $32.48 on Friday. CymaBay Therapeutics, Inc. has a 1-year low of $7.26 and a 1-year high of $32.50. The company has a 50-day moving average of $32.09 and a 200 day moving average of $23.99. The firm has a market cap of $3.73 billion, a PE ratio of -33.48 and a beta of 0.32.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.04). The business had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.42 million. Sell-side analysts anticipate that CymaBay Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

CymaBay Therapeutics Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC).